The stability of pathogen-specific DNA or RNA amplification targets in clinical samples following short-term storage at room temperature, 4°C, and ؊80°C was assessed by real-time PCR. In purified nucleic acid extracts, both DNA and RNA targets were stable for up to 30 days, irrespective of storage temperature. In unextracted samples, temperature-dependent loss of targets (P < 0.05) was observed in serum and cerebrospinal fluid specimens, while no changes were observed for EDTA blood samples. N ucleic acid amplification tests (NAATs) to detect infectious pathogens are now widely used in clinical microbiology laboratories. Although these assays provide high sensitivity, high specificity, and rapid turnaround time, special laboratory practice and procedures are required to avoid false-positive and false-negative results (1, 2). Optimal application of NAATs depends on a number of preanalytical factors, such as specimen collection, transport, and storage conditions (3, 4). These factors impact the stability of pathogen-associated nucleic acids (NA), which must be protected from physical, chemical, or enzymatic degradation during specimen transport and handling. The most important threats to the stability of NA targets in clinical samples are nucleases, such as DNases and RNases, which may be released from lysed human cells and microorganisms (5). In real-life clinical situations, questions arise over whether clinical samples or NA extracts, left at room temperature (RT) for a few days or stored in the refrigerator for a week, are still valid for molecular testing. Although there are published guidelines for the collection, transport, and storage of specimens for molecular tests, described by CLSI (4), they are based mostly on opinions and limited experimental data. Published data on the stability of pathogen-specific amplification targets are also limited to individual pathogens and/or specimen types (3, 4, (6) (7) (8) (9) (10) 12) . Therefore, in this study, we undertook a broader study to compare the stability of extracted and unextracted clinical samples over time and at different temperatures.
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To determine the short-term storage stability of purified DNA and RNA, NA was extracted from known positive specimens containing the following: Neisseria meningitidis in EDTA blood, cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in serum, and influenza A virus in nasopharyngeal washes (NPW). All samples were extracted using the QIAsymphony virus/bacteria kit in an automated DNA extraction platform QIAsymphony SP (Qiagen) except for EDTA blood, which was extracted manually using the QIAamp DNA blood minikit (Qiagen). Purified eluates were stored in aliquots under sterile conditions at room temperature (RT) (22 to 25°C), 4°C, and Ϫ80°C for 0 to 30 days.
For unextracted samples, the target pathogen and the specimen types were chosen so that they (i) represent the most common specimen type for the respective pathogen and (ii) had not previously been studied. EDTA blood, serum, cerebrospinal fluid (CSF), and NPW samples were spiked with an N. meningitidis B strain (ATCC 13090), a CMV patient isolate, a human enterovirus 70 strain (ATCC VR-836), and an influenza A virus patient isolate, respectively, within 4 h of collection (see Methods in the supplemental material). NA from spiked samples was extracted in the same way following storage at RT, 4°C, and Ϫ80°C for 0 to 16 days. Extracted nucleic acids were analyzed either by in-house (see methods and Table S1 in the supplemental material) or commercial, probe-based, real-time PCR assays. Human enterovirus RNA was detected using a commercial eQ-PCR EnV detection kit (Trimgen Corporation). For kinetic analysis, threshold cycle (C T ) values for each pathogen were plotted against the number of days the samples were stored at different temperatures. The half-lives of pathogen-associated nucleic acid targets were obtained from the linear equation (see Methods in the supplemental material). For average analysis, fold changes in the relative quantity of amplification targets were calculated based on C T values using the equation FC ϭ 2
ϪdCT , where dCT ϭ (C T,day x Ϫ C T,day 0 ) (11). The percent loss of targets was calculated from fold changes from the quantity of targets at day 0. Statistical significance was calculated by paired and 2-tailed Student's t test, and a P value of Ͻ0.05 was considered to be statistically significant. Statistical differences between multiple experimental groups were calculated by analysis of variance (ANOVA) followed by a posttest using Bonferroni correction at a 95% confidence interval.
There was no loss of extracted N. meningitidis, CMV, and EBV DNA derived from EDTA blood and serum samples after storage at RT, 4°C, and Ϫ80°C for 0, 3, 7, 14, and 30 days (Fig.  1Ai , Ci, Di). To account for sample-to-sample variation, we performed further tests on additional samples at days 0 and 30 of storage at different temperature and found no significant differences in the relative quantity of specific amplification targets (Fig. 1Aii , Cii, Dii). In general, DNA, when purified and stored in a preferred buffer such as Tris-EDTA (pH 7.2), is considered to be stable for at least 1 year at 2 to 8°C and for longer terms at Ϫ70°C or lower (3). However, it is important to note that the DNA purity could be dependent on the specimen type and the extraction methods, which could subsequently influence the stability of purified DNA. Our findings suggest that DNA extracted from EDTA blood or serum samples, using an automated and magnetic bead-based extraction method, may be safely stored at RT or lower without any loss for up to 1 month. Unlike the case with DNA, it is recommended that purified RNA be stored at Ϫ70°C or lower and at a slightly alkaline pH (7.1 to 7.5) (3). In our lab setting, we observed a small (ϳ1 C T ; P Ͻ 0.05) loss of influenza A RNA, which was not temperature dependent (between RT to Ϫ80°C), in purified NPW extracts following storage for a period of 1 month (Fig.  1B) . These results indicate that temporary storage of extracted nucleic acids from clinical samples at RT or 4°C is unlikely to affect NAAT results.
Unlike extracted samples, where purified DNA and RNA molecules are maintained in a defined buffer, crude clinical samples represent a complex biological environment, where an interplay of degradative proteases and nucleases may determine the fate of pathogen-associated amplification targets. Previously published observations on the stability of microbial DNA in clinical samples include the following: (i) Trichomonas vaginalis DNA was stable for 1 day at RT and 3 days at 4°C in urine samples (6), (ii) spiked Treponema pallidum DNA in CSF was detectable after 96 h of storage at RT and 4°C (12), (iii) HSV DNA in positive clinical specimens remained stable for at least 16 months at Ϫ20°C (7), and (iv) HBV DNA in positive plasma samples was stable at 25°C and at 5°C for at least 25 days (8) , whereas in serum it was stable only for 5 days at 4°C and Ϫ70°C and less stable at RT (10). Our results on the stability of spiked N. meningitidis DNA in EDTA blood and CMV DNA in serum and EDTA blood samples correlate well and complement these observations. Whereas both N. meningitidis and CMV DNA were highly stable in EDTA blood for 2 weeks at any storage temperature used, significant loss (P Ͻ 0.05 by ANOVA and posttest) of CMV DNA was observed in serum samples in a temperature-dependent manner ( Fig. 2A and B) . The half-life of CMV DNA based on PCR assays was Ͻ1, 2, and 3 days when stored at RT, 4°C, and Ϫ80°C, respectively (Table 1) .
Although a loss of RNA targets in crude samples is expected during storage, unless frozen, we noted no dramatic, logarithmic decrease in human enterovirus and influenza A RNA levels in CSF and NPW samples, respectively, after 2 weeks. A small but statistically significant reduction of enterovirus RNA (65%; P Ͻ 0.05) at RT and influenza RNA (Ͼ50%; P Ͻ 0.001) at all tem- peratures was observed (Fig. 2C and D) . The half-life of enterovirus RNA in CSF samples at RT was 9 days (Table 1) , which correlates well with that of HIV-1 RNA (7 days) in plasma samples, as previously reported (8) . Similarly, at 4°C, enterovirus RNA maintained its integrity for approximately 2 weeks in this study, as seen in a previous HIV-1 study (8) . The results of influenza A RNA in NPW samples were somewhat surprising, as no temperature-dependent effects were detected. One limitation of this study is that we did not analyze RNA stability in EDTA blood samples. However, a previous study found HCV RNA stable in EDTA blood for up to 96 h (9) , similar to what we observed for DNA targets.
In conclusion, we observed minimal loss of pathogen NAAT targets for both extracted and unextracted clinical samples within a few days of specimen collection. None of the NAAT targets became undetectable during the study period, which was limited to 1 month and 2 weeks, for pure extracts and crude samples, respectively, to represent most common scenarios in a diagnostic microbiology laboratory. The temperature-dependent loss of targets in serum and CSF samples indicates possible enzymatic degradation. In contrast, EDTA blood samples were found to be the most protective medium for nucleic acid stability. This may be because EDTA sequesters metal ions required for enzymatic activity and thus inhibits nucleases and proteases. Based on these observations, we conclude that, if a processing delay is unavoidable, EDTA blood or plasma samples are preferable to serum samples for real-time PCR detection of bacterial or viral pathogens. 6 to 31.7 for CMV, 32.7 to 34.1 for enterovirus, and 33.9 to 37.1 for influenza A. Intraassay variation between duplicate runs was Ͻ1 C T . Error bars ϭ SEM; statistical significance compared to data at day 0 calculated by pairwise Student's t test (2-tailed); *, P Ͻ 0.05; ***, P Ͻ 0.001. Multiple group comparisons for CMV DNA levels in serum samples were made by ANOVA and posttest (95% confidence interval), indicating a statistically significant (P Ͻ 0.05) difference between different groups.
TABLE 1
Half-life and percentage loss of pathogen-specific amplification targets in different types of clinical specimens
